N=132, %
All Grade
Grade 3/4
Hyperglycemia
47.0
23.5
Nausea
46.2
2.3
Diarrhea
37.9
2.3
Decreased appetite
37.1
1.5
Fatigue
28.8
1.5
Vomiting
27.3
2.3
Stomatitis
18.2
0
Dysguesia
13.6
0
Dyspepsia
12.9
0
Rash
12.9
0
Weight decrease
11.4
0
Dry skin
10.6
0
Maculopapular rash
10.6
2.3
Alpelisib Phase I Study (X2101 Single Agent):
Safety Results
Juric D, et al.
Lancet Oncology
2015 – manuscript in preparation.
Adverse events (all Grade ≥10% of patients) Suspected to be
Treatment-Related, Across Dose Levels
1
6
0
9
0
4
3
6
8
1
